DXCM
Dexcom insider trading
Health Care · Net selling
Close · Oct 5, 2026
$86.90
+31.0% over 12 months
Share price and insider trades
DXCM closeInsider buyInsider sale
Bought, 12 months$1.0M
Sold, 12 months$12.6M
Insiders buying1
Insiders selling9
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.6×Last 5 sessions
Insiders' paper profit+$580KOn all tracked purchases +57.9%
Summary
Over the past 12 months, 1 Dexcom insider reported open-market purchases totaling $1.0M, while 9 insiders reported sales totaling $12.6M. 30 of 30 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 52 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 30SEC | Sadie SternEvp Chief People & Culture Off | Sell Plan | 2,565 | $86.15 | $221K | +0.9% | — |
| Sep 16SEC | Nicholas AugustinosDirector | Sell Plan | 6,539 | $84.04 | $550K | +3.4% | — |
| Sep 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $84.04 | $143K | +3.4% | — |
| Sep 16SEC | Nicholas AugustinosDirector | Sell Plan | 1,550 | $84.02 | $130K | +3.4% | — |
| Sep 14SEC | Jereme M SylvainEvp, Chief Financal Officer | Sell Plan | 3,638 | $83.27 | $303K | +4.4% | — |
| Aug 28SEC | Sadie SternEvp Chief People & Culture Off | Sell Plan | 2,565 | $88.37 | $227K | -1.7% | — |
| Aug 24SEC | Kevin R SayerChair | Sell Plan | 19,308 | $89.71 | $1.7M | -3.1% | — |
| Aug 24SEC | Kevin R SayerChair | Sell Plan | 7,351 | $90.78 | $667K | -4.3% | — |
| Aug 24SEC | Kevin R SayerChair | Sell Plan | 97 | $91.41 | $9K | -4.9% | — |
| Aug 17SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $91.93 | $156K | -5.5% | — |
| Aug 13SEC | Bridgette P HellerDirector | Sell Plan | 1,012 | $88.29 | $89K | -1.6% | — |
| Aug 4SEC | Mark G FolettaDirector | Sell Plan | 2,000 | $85.32 | $171K | +1.9% | — |
| Aug 4SEC | Mark G FolettaDirector | Sell Plan | 2,000 | $80.00 | $160K | +8.6% | — |
| Jul 21SEC | Kevin R SayerChair | Sell Plan | 26,756 | $76.32 | $2.0M | +13.9% | — |
| Jul 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $74.42 | $127K | +16.8% | — |
| Jul 7SEC | Kevin R SayerChair | Sell Plan | 26,756 | $72.00 | $1.9M | +20.7% | — |
| Jun 17SEC | Mark G FolettaDirector | Sell Plan | 3,801 | $74.10 | $282K | +17.3% | — |
| Jun 17SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $75.55 | $128K | +15.0% | — |
| Jun 17SEC | Mark G FolettaDirector | Sell Plan | 199 | $74.82 | $15K | +16.1% | — |
| Jun 5SEC | Jon ColemanEvp, Chief Commercial Officer | Sell Plan | 4,911 | $74.13 | $364K | +17.2% | — |
| Jun 5SEC | Jon ColemanEvp, Chief Commercial Officer | Sell Plan | 4,912 | $73.00 | $359K | +19.0% | — |
| May 26SEC | Kevin R SayerChair | Sell Plan | 26,759 | $72.00 | $1.9M | +20.7% | — |
| May 19SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $59.91 | $102K | +45.1% | — |
| May 14SEC | Bridgette P HellerDirector | Sell Plan | 1,012 | $60.01 | $61K | +44.8% | — |
| Apr 16SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $63.04 | $107K | +37.8% | — |
| Mar 18SEC | Michael Jon BrownGeneral Counsel | Sell Plan | 1,700 | $64.85 | $110K | +34.0% | — |
| Feb 17SEC | Bridgette P HellerDirector | Sell Plan | 1,012 | $68.01 | $69K | +27.8% | — |
| Nov 17SEC | Richard Alexander CollinsDirector | Sell Plan | 2,906 | $59.05 | $172K | +47.2% | — |
| Nov 12SEC | Bridgette P HellerDirector | Sell Plan | 1,012 | $58.07 | $59K | +49.6% | — |
| Nov 10SEC | Jacob Steven LeachCOO, President | Buy | 15,700 | $54.98 | $863K | +58.1% | — |
| Nov 10SEC | Richard Alexander CollinsDirector | Sell Plan | 3,948 | $55.17 | $218K | +57.5% | — |
| Nov 10SEC | Jacob Steven LeachCOO, President | Buy | 2,500 | $55.43 | $139K | +56.8% | — |
Insiders at Dexcom
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Kevin R SayerChair | — | $8.3M | Aug 24, 2026 | — |
| Jacob Steven LeachCEO, President | $1.0M | — | Aug 25, 2026 | — |
| Michael Jon BrownGeneral Counsel | — | $873K | Sep 16, 2026 | — |
| Jon ColemanEvp, Chief Commercial Officer | — | $723K | Jun 5, 2026 | — |
| Nicholas AugustinosDirector | — | $680K | Sep 16, 2026 | — |
| Mark G FolettaDirector | — | $627K | Aug 4, 2026 | — |
| Sadie SternEvp Chief People & Culture Off | — | $448K | Sep 30, 2026 | — |
| Richard Alexander CollinsDirector | — | $389K | Jun 1, 2026 | — |
| Jereme M SylvainEvp, Chief Financal Officer | — | $303K | Sep 14, 2026 | — |
| Bridgette P HellerDirector | — | $278K | Aug 13, 2026 | — |
| Glenn S BoehnleinDirector | — | — | Sep 10, 2026 | — |
| Renee D GalaDirector | — | — | Jun 1, 2026 | — |
| Euan A. AshleyDirector | — | — | Jun 1, 2026 | — |
| Rimma DriscollDirector | — | — | Jun 1, 2026 | — |
| Albert Frederick Osterloh IVDirector | — | — | Jun 1, 2026 | — |
| Kyle MaladyDirector | — | — | Jun 1, 2026 | — |
| Steven R AltmanDirector | — | — | Jun 1, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about DXCM insiders
Are Dexcom insiders buying DXCM stock?
In the past 12 months, 1 insiders reported open-market purchases of DXCM worth $1.0M. The latest was COO, President Jacob Steven Leach bought $863K of DXCM at $54.98 — first open-market purchase in our records.
Are Dexcom insiders selling DXCM stock?
9 insiders reported sales worth $12.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.